Summary of Significant Accounting Policies (Details)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023
Summary of Significant Accounting Policies [Line Items]
Comprehensive (loss) of foreign currency translation adjustment	$ (67,332)	$ (20,861)	$ 6,460	$ 51,316	$ (15,267)	$ 663	$ (81,733)	$ 36,712
Currency of subsidiaries	350			1,485			1,467	2,952
Carrying amount									$ 1,462,084
Fair market value of asset									9,063,000
Fair market value									0
Exceeded of fair market values									1,880,000
Impaired									3,342,084
Reduced asset									0
After impairment									9,063,000
Loss in the amount				9,063,000				9,063,000
Carrying amount of the IP R&D assets	$ 151,138			$ 132,880			455,345	481,027
Deferred income tax benefit								$ (2,345,025)
CBR Pharma Subsidiary [Member]
Summary of Significant Accounting Policies [Line Items]
Carrying amount									10,943,000
Fair market value									9,063,000
Exceeded of fair market values									1,462,084
British pound [Member]
Summary of Significant Accounting Policies [Line Items]
Foreign currency exchange rate	1.338						1.338			1.273
Weighted average exchange rate	1.301			1.2655			1.277	2,442
US dollar [Member]
Summary of Significant Accounting Policies [Line Items]
Foreign currency exchange rate	1						1			1
Weighted average exchange rate	1			1			1	1
IP R&D assets [Member]
Summary of Significant Accounting Policies [Line Items]
Carrying amount									12,405,084
Reduced asset									9,063,000
Carrying amount of the IP R&D assets
Deferred income tax benefit								2,300,000
One Eight Zero LP subsidiary [Member]
Summary of Significant Accounting Policies [Line Items]
Carrying amount									$ 9,063,000
Carrying amount of the IP R&D assets								$ 0